Levonadifloxacin
 | |
| Clinical data | |
|---|---|
| Trade names | Emrok |
| Other names | (S)-(-)-Nadifloxacin |
| Routes of administration | Parenteral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
| |
Levonadifloxacin (trade name Emrok) is an antibiotic drug of the
racemic drug nadifloxacin
.
It is approved in India for the treatment of skin and soft tissue infections of
resistant strains of bacteria including Streptococcus pneumoniae, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis.[4]
Levonadifloxacin has poor
oral bioavailability. A prodrug of levonadifloxacin with high oral bioavailability, alalevonadifloxacin, has been developed to mitigate this problem.[5]